Trials / Recruiting
RecruitingNCT06581315
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Efficacy and Safety of Donafenib as Adjuvant Therapy for Postoperative Patients With High-Risk Recurrent Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donafenib | Donafenib 100 mg twice daily (BID) |
Timeline
- Start date
- 2024-08-28
- Primary completion
- 2027-08-30
- Completion
- 2032-08-30
- First posted
- 2024-09-03
- Last updated
- 2024-09-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06581315. Inclusion in this directory is not an endorsement.